FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113235032> ?p ?o ?g. }

• W2113235032 endingPage "360" @default.
• W2113235032 startingPage "340" @default.
• W2113235032 abstract "A systematic review of chemotherapy trials in several tumour types was performed by The Swedish Council of Technology Assessment in Health Care (SBU). The procedures for the evaluation of the scientific literature are described separately (Acta Oncol 2001; 40: 155-65). This overview on chemotherapy for epithelial ovarian cancer is based on a total of 176 scientific reports. Five meta-analyses including 17,291 patients, 33 prospective randomised studies including 12,340 patients, 36 prospective studies including 3,593 patients and one retrospective study including 421 patients. The studies include approximately 33,642 patients. The conclusions reached can be summarized into the following points: Radically operated patients with low-risk early ovarian cancer (stage IA or IB non-clear-cell well-differentiated carcinomas or borderline tumours) have a very good prognosis and there is no indication for adjuvant therapy. Radically operated patients with high-risk early ovarian cancer (clear cell carcinomas or FIGO stage IA or IB moderately or poorly differentiated carcinomas or stage IC) have a substantial risk for micrometastatic disease. However, the role of adjuvant chemotherapy is unclear and such therapy should, thus, only be used within clinical trials. The median overall survival for patients with advanced (FIGO stages II-IV) ovarian cancer randomised to paclitaxel/platinum-containing chemotherapy in three large studies ranged between 36-39 months. Compared with historical data, this represents a six to seven times longer median survival time than after surgery only. The probability for long-term survival for patients treated with a paclitaxel/platinum combination is too early to define. In two prospective randomised trials in advanced ovarian cancer, paclitaxel in combination with cisplatin has provided a survival benefit over cyclophosphamide/cisplatin. Based on these trials, paclitaxel/cisplatin is considered to be the standard treatment. This choice of standard therapy might, however, be questioned based on the results of the hitherto largest randomised study in advanced ovarian cancer, ICON3, which is, as yet only available in abstract form. It compared paclitaxel/carboplatin with carboplatin only or a platinum combination (cyclophosphamide/doxorubicin/cisplatin). There were no statistically significant differences in progression-free or overall survival. The drug regimen in the control arms of the previous studies showing superiority of the paclitaxel-cisplatin combination may not have been the optimal non-paclitaxel platinum-containing regimen. Three randomised studies have compared carboplatin/paclitaxel with cisplatin/paclitaxel. All three are hitherto only published as abstracts with short follow-up precluding survival analyses. None of them shows any difference in response rates. All three show less toxicity and one also better quality of life with carboplatin. Thus, there are preliminary data supporting the substitution of cisplatin with carboplatin. Intraperitoneal therapy with cisplatin caused improved survival compared with intravenous therapy in one ramdomised study. Further studies have shown trends to better survival and longer progression-free interval with intraperitoneal therapy. The accrual to studies on intraperitoneal chemotherapy has been poor reflecting that it is a cumbersome and not easily accepted treatment. In advanced ovarian cancer, no convincing advantage has been shown from more dose-intensive chemotherapy, without cytokines or bone marrow stem cell support, compared with standard doses. High response rates are achieved with high-dose chemotherapy with stem cell support in the salvage situation but response duration is short. Phase III studies evaluating high-dose chemotherapy in the first-line situation are ongoing. Until supportive controlled clinical trials are presented, high-dose chemotherapy should be confined to clinical trials. Tumour response is frequently observed on re-treatment with the same drugs as given first-line in patients sensitive to first-line platinum-based chemotherapy with a long progression-free interval. Thus, in these patients treatment with a platinum/paclitaxel combination might be recommended. albeit based on limited data. In patients resistant to first-line therapy, a number of single agents induce tumour responses in the range of 10-30%. The literature does not permit general treatment recommendations in these patients, which are recommended to be included in controlled clinical trials." @default.
• W2113235032 created "2016-06-24" @default.
• W2113235032 creator A5001084766 @default.
• W2113235032 creator A5024074968 @default.
• W2113235032 creator A5057158252 @default.
• W2113235032 date "2001-03-01" @default.
• W2113235032 modified "2023-09-25" @default.
• W2113235032 title "A Systematic Overview of Chemotherapy Effects in Ovarian Cancer" @default.
• W2113235032 cites W108614791 @default.
• W2113235032 cites W113476337 @default.
• W2113235032 cites W1535958986 @default.
• W2113235032 cites W1543697093 @default.
• W2113235032 cites W1696098959 @default.
• W2113235032 cites W1758230404 @default.
• W2113235032 cites W1758361781 @default.
• W2113235032 cites W1770712556 @default.
• W2113235032 cites W1831044128 @default.
• W2113235032 cites W1840914753 @default.
• W2113235032 cites W1845286775 @default.
• W2113235032 cites W1845622004 @default.
• W2113235032 cites W1857437878 @default.
• W2113235032 cites W1863225814 @default.
• W2113235032 cites W1873154181 @default.
• W2113235032 cites W1880772556 @default.
• W2113235032 cites W189085520 @default.
• W2113235032 cites W1902459117 @default.
• W2113235032 cites W1905580151 @default.
• W2113235032 cites W1913802169 @default.
• W2113235032 cites W1917258958 @default.
• W2113235032 cites W1922975641 @default.
• W2113235032 cites W1930308991 @default.
• W2113235032 cites W1936253731 @default.
• W2113235032 cites W1939163116 @default.
• W2113235032 cites W1940922428 @default.
• W2113235032 cites W1944392621 @default.
• W2113235032 cites W1962492094 @default.
• W2113235032 cites W1964431777 @default.
• W2113235032 cites W1965738966 @default.
• W2113235032 cites W1967119242 @default.
• W2113235032 cites W1968497980 @default.
• W2113235032 cites W1970846523 @default.
• W2113235032 cites W1971253600 @default.
• W2113235032 cites W1971445820 @default.
• W2113235032 cites W1975044674 @default.
• W2113235032 cites W1976837208 @default.
• W2113235032 cites W1981534406 @default.
• W2113235032 cites W1987980065 @default.
• W2113235032 cites W1994880203 @default.
• W2113235032 cites W1995231321 @default.
• W2113235032 cites W1996131136 @default.
• W2113235032 cites W2002363083 @default.
• W2113235032 cites W2002512099 @default.
• W2113235032 cites W2003422757 @default.
• W2113235032 cites W2003428752 @default.
• W2113235032 cites W2007331193 @default.
• W2113235032 cites W2012338478 @default.
• W2113235032 cites W2014869690 @default.
• W2113235032 cites W2016029827 @default.
• W2113235032 cites W2017076579 @default.
• W2113235032 cites W2017338688 @default.
• W2113235032 cites W2019039016 @default.
• W2113235032 cites W2019042500 @default.
• W2113235032 cites W2019063894 @default.
• W2113235032 cites W2019879643 @default.
• W2113235032 cites W2025620410 @default.
• W2113235032 cites W2027862395 @default.
• W2113235032 cites W2028561388 @default.
• W2113235032 cites W2032844075 @default.
• W2113235032 cites W2035152690 @default.
• W2113235032 cites W2038166913 @default.
• W2113235032 cites W2038732363 @default.
• W2113235032 cites W2038890667 @default.
• W2113235032 cites W2048960362 @default.
• W2113235032 cites W2049087678 @default.
• W2113235032 cites W2051474963 @default.
• W2113235032 cites W2052332322 @default.
• W2113235032 cites W2052846363 @default.
• W2113235032 cites W2055992280 @default.
• W2113235032 cites W2061672736 @default.
• W2113235032 cites W2062701661 @default.
• W2113235032 cites W2065393338 @default.
• W2113235032 cites W2068571575 @default.
• W2113235032 cites W2074353525 @default.
• W2113235032 cites W2075557081 @default.
• W2113235032 cites W2076024279 @default.
• W2113235032 cites W2076446092 @default.
• W2113235032 cites W2077306345 @default.
• W2113235032 cites W2078072518 @default.
• W2113235032 cites W2082369433 @default.
• W2113235032 cites W2086381594 @default.
• W2113235032 cites W2088865525 @default.
• W2113235032 cites W2090307961 @default.
• W2113235032 cites W2097029797 @default.
• W2113235032 cites W2097105130 @default.
• W2113235032 cites W2107003788 @default.
• W2113235032 cites W2111912711 @default.
• W2113235032 cites W2112673873 @default.
• W2113235032 cites W2112711252 @default.

• next